Wlaź P, Ebert U, Löscher W
Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Hannover, Germany.
Eur J Neurosci. 1994 Nov 1;6(11):1710-9. doi: 10.1111/j.1460-9568.1994.tb00563.x.
(+)-HA-966 [R-(+)-3-amino-1-hydroxypyrrolid-2-one], a functional antagonist at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor/ion channel complex, was evaluated in amygdala-kindled rats, a model of epilepsy recently shown to exhibit enhanced susceptibility to the adverse effects of competitive and non-competitive NMDA receptor antagonists. Since (+)-HA-966 displays weak partial agonistic effects at the glycine site (approximately 10% efficacy of glycine), D-cycloserine, a glycine ligand with much higher intrinsic activity, was evaluated in kindled rats for comparison. Following drug administration, electrographic activity was recorded from the basolateral amygdala (i.e. the focal site) as well as the ipsilateral piriform cortex, ventral hippocampus and nucleus accumbens. In addition to the evaluation of original recordings, power spectrum analysis was used to delineate drug effects. (+)-HA-966 (20-40 mg/kg i.p.) induced marked alterations in electrographic recordings, including increases in amplitude and isolated spiking, i.e. signs of paroxysmal activity. The severity or duration of fully kindled seizures was not changed by (+)-HA-966, but the drug dramatically increased the duration of immobilization and limbic seizure activity following a kindled motor seizure. In contrast to (+)-HA-966, D-cycloserine did not induce any electrographic changes, even when administered in much higher doses than (+)-HA-966. The changes in electrographic recordings seen after administration of (+)-HA-966 in kindled rats were almost absent in non-kindled rats, indicating that kindling had increased the sensitivity to the paroxysmal effects of the glycine/NMDA receptor ligand. The data indicate that functional glycine/NMDA antagonists with low intrinsic efficacy may bear the risk of proconvulsant activity.
(+)-HA-966 [R-(+)-3-氨基-1-羟基吡咯烷-2-酮]是N-甲基-D-天冬氨酸(NMDA)受体/离子通道复合物上甘氨酸调节位点的功能性拮抗剂,在杏仁核点燃大鼠中进行了评估,该癫痫模型最近显示出对竞争性和非竞争性NMDA受体拮抗剂的不良反应易感性增强。由于(+)-HA-966在甘氨酸位点表现出较弱的部分激动作用(约为甘氨酸功效的10%),因此对具有更高内在活性的甘氨酸配体D-环丝氨酸在点燃大鼠中进行了评估以作比较。给药后,从基底外侧杏仁核(即病灶部位)以及同侧梨状皮质、腹侧海马和伏隔核记录脑电图活动。除了对原始记录进行评估外,还使用功率谱分析来描述药物作用。(+)-HA-966(20-40mg/kg腹腔注射)引起脑电图记录的显著改变,包括振幅增加和孤立的尖峰放电,即阵发性活动的迹象。(+)-HA-966并未改变完全点燃癫痫发作的严重程度或持续时间,但该药物显著增加了点燃性运动性癫痫发作后固定和边缘性癫痫发作活动的持续时间。与(+)-HA-966相反,即使给予比(+)-HA-966高得多的剂量,D-环丝氨酸也未引起任何脑电图变化。在未点燃的大鼠中,给予(+)-HA-966后所见的脑电图记录变化几乎不存在,这表明点燃增加了对甘氨酸/NMDA受体配体阵发性作用的敏感性。数据表明,内在效力低的功能性甘氨酸/NMDA拮抗剂可能具有促惊厥活性的风险。